AusPharm.net.au - AusPharm Continuing Professional Development

To generate a report of the AusPharm Continuing Professional Development activities you have completed for a specified time period (and, if desired, the number of times you have posted to AusPharmList over the same time period), click here. Please note, you need to be logged in to do this.

The Continuing Professional Development activities below will remain active for 12 months from the date of publication. You will be able to do any one of them at any time. ie ALL activities remain 'active' not just the current activity.

While every effort has been made to ensure that material presented is accurate and up to date, new evidence is continually uncovered and what is accurate one week may not stay accurate for long.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 58 :: Chris Alderman : 16/5/2013 : The next in our 2013 series of continuing professional development activities is the RGH E-Bulletin Digest No. 58.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 49-7 → 49-10 (February/March 2013).

You can access these E-Bulletins individually here or as a group here (the Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Understand the possible influence of medications on wound healing
Outline various approaches to the management of haematuria associated with BPH
Understand the possible effects of aspirin use upon the incidence AMD
Describe the characteristics of the complementary medicine Methylsulfonylmethane (MSM).

This activity has been accredited for 0.5hr of Group One CPD (0.5 CPD Credits) that may be converted to 1 Group Two CPD Credit upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1305AP1.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Professional Development activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.

Click here to do this Continuing Professional Development activity.

Medication use in the ‘very old’ independent person :: Jenny Gowan : 2/5/2013 : The next in our 2013 series of continuing professional development activities is "Medication use in the ‘very old’ independent person" by Dr Jenny Gowan.

Learning objectives

After completing this activity, pharmacists should be able to:

Predict medications which require caution for use in the very old
Determine considerations that may need to be taken into account when discussing medication issues with an older independent person
Minimise risk of adverse drug reactions in the very old person
Modify guidelines and targets to optimise the quality of life for the very old.

This activity has been accredited for 1 hour of Group One CPD (1 CPD Credit) that may be converted to 2 Group Two CPD Credits upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1305AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2, 6.2.3, 7.1.2, 7.1.3, 7.1.4, 7.2.1, 7.2.2, 7.2.3.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

Update on Vitamin D deficiency :: Debbie Rigby : 18/4/2013 : Learning objectives

After completing this activity, pharmacists should be able to:

Understand the association between vitamin D deficiency and various conditions
Interpret vitamin D levels to identify deficiency or insufficiency
Counsel patients on appropriate dose of vitamin D supplement.

This activity has been accredited for 1 hour of Group One CPD (1 CPD Credit) that may be converted to 2 Group Two CPD Credits upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1304AP1.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2, 6.2.3, 7.1.2, 7.1.3, 7.1.4, 7.2.1, 7.2.2, 7.2.3.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 57 :: Chris Alderman : 21/3/2013 : The next in our 2013 series of continuing professional development activities is the RGH E-Bulletin Digest No. 57.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 49-3 → 49-6 (January/February 2013).

You can access these E-Bulletins individually here or as a group here (the Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Discuss the important issues to consider with respect to drug therapy during electroconvulsive therapy
Describe key findings from recent research into the use of apixaban to prevent VTE in people with AF
Outline findings of recent research into the use of strontium as a treatment for osteoporosis in men
Discuss the clinical pharmacology of serelaxin.

This activity has been accredited for 0.5hr of Group One CPD (0.5 CPD Credits) that may be converted to 1 Group Two CPD Credit upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1304AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Professional Development activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 56 :: Chris Alderman : 7/3/2013 : The next in our 2013 series of continuing professional development activities is the RGH E-Bulletin Digest No. 56.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 48-10 → 49-2 (December 2012/January 2013).

You can access these E-Bulletins individually here or as a group here (the Digest pdf includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Describe the place of atypical antipsychotic drugs in the management of obsessive compulsive disorder
Understand the pharmacological treatment options available for the management of urolithiasis
Discuss issues regarding the use of medications during periods of extreme hot weather
Describe recent evidence regarding the adverse metabolic impact of antipsychotic drugs.

This activity has been accredited for 0.5hr of Group One CPD (0.5 CPD Credits) that may be converted to 1 Group Two CPD Credit upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1303AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Professional Development activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.

Click here to do this Continuing Professional Development activity.

Chronic Obstructive Pulmonary Disease (COPD) :: Angus Thompson : 21/2/2013 : Learning objectives

After completing this module pharmacists should be able to::

Outline the etiology and pathophysiology of COPD
Describe the typical presenting features of COPD
Discuss the approach to acute and chronic COPD treatment
Identify opportunities to optimise the management of COPD.

This activity has been accredited for 1 hour of Group One CPD (1 CPD Credit) that may be converted to 2 Group Two CPD Credits upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1302AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 7.1.2, 7.1.3, 7.2.2, 7.2.3.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 55 :: Chris Alderman : 7/2/2013 : The first in our 2013 series of continuing professional development activities is the RGH E-Bulletin Digest No. 55.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 48-6 → 48-9 ⇔ November/December 2012).

You can access these E-Bulletins individually here or as a group here (the Digest pdf includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Specify the latest Australian targets for cardiovascular risk reduction for people with type II diabetes
Outline the manifestations and treatment of familial cold auto-inflammatory syndrome
Discuss issues regarding gluten content of oral pharmaceutical products
Understand recent evidence that has emerged regarding bleeing risk associated with the use of enoxaparin in patients with moderate renal impairment.

This activity has been accredited for 0.5hr of Group One CPD (0.5 CPD Credits) that may be converted to 1 Group Two CPD Credit upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1302AP1.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Professional Development activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.

Click here to do this Continuing Professional Development activity.

Aspirin – who needs it? :: Debbie Rigby : 13/12/2012 : Learning objectives

By the end of this module you should feel confident to be able to:

Describe the mechanism of action of aspirin
List the indications for use of aspirin
Understand the two forms of thrombus and their risk factors
Discuss current evidence and controversies for the role of aspirin in primary and secondary prevention of cardiovascular disease
Discuss current evidence and controversies for the role of aspirin in primary and secondary prevention of venous thrombembolism
Determine appropriate therapy for prevention of stroke in patients with atrial fibrillation for an individual patient
Assess and interpret gastrointestinal bleeding risk for an individual patient.

This activity has been accredited for 1 hour of Group One CPD (1 CPD Credit) that may be converted to 2 Group Two CPD Credits upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1212AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2, 6.2.3, 7.1.2, 7.1.3, 7.1.4, 7.2.1, 7.2.2, 7.2.3.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 54 :: Chris Alderman : 29/11/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 54.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 48-2 → 48-5 ⇔ October/November 2012).

You can access these E-Bulletins individually here or as a group here (the Digest pdf includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Understand the manifestations and possible treatment of Hutchinson-Gilford progeria syndrome
Outline clinically important drug interactions with rifampicin
Discuss the current treatment options for obsessive compulsive disorder
Describe the principles of the potential application of exanatide as a drug to facilitate weight loss.

This activity has been accredited for 0.5hr of Group One CPD (0.5 CPD Credits) that may be converted to 1 Group Two CPD Credit upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1211AP1.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

Medication Overuse Headache :: Debbie Rigby : 15/11/2012 : Learning objectives

After completing this activity, pharmacists should be able to:

Be aware of NICE 2012 guidelines for Headaches
Understand the aetiology and risk factors for medication overuse headache
Assess patients for medication overuse headache
Counsel patients on risks of overuse of analgesics
Offer advice and education to encourage withdrawal treatment
Follow up regularly to prevent relapse of medication overuse.

This activity has been accredited for 1 hour of Group One CPD (1 CPD Credit) that may be converted to 2 Group Two CPD Credits upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1211AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2, 6.2.3, 7.1.2, 7.1.3, 7.1.4, 7.2.1, 7.2.2, 7.2.3.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 53 :: Chris Alderman : 25/10/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 53.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 47-10 → 48-1 ⇔ September/October 2012).

You can access these E-Bulletins individually here or as a group here (the Digest pdf includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

List clinically significant drug interactions with clozapine
Discuss the clinical pharmacology of rasagiline
Understand the current evidence for optimal duration of dual antiplatelet therapy
Outline a range of issues with respect to use of complementary and alternative medicines in the peri-operative period.

This activity has been accredited for 0.5hr of Group One CPD (0.5 CPD Credits) that may be converted to 1 Group Two CPD Credit upon successful completion of the corresponding assessment for inclusion on an individual pharmacist's CPD Record.
Accreditation number: A1210AP2.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 52 :: Chris Alderman : 11/10/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 52.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 47-6 → 47-9 ⇔ August/September 2012).

You can access these E-Bulletins individually here or as a group here (the Digest pdf includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Understand the relative risk for arterial thrombotic events associated with combined oral contraceptive use
Discuss the clinical features and drug treatment of Huntington's disease
Specify considerations that need to be taken into account when crushing solid oral dose forms
Describe clinical issues relevant to atypical fractures associated with bisphosphonate use.

This activity has been accredited by the Australian College of Pharmacy as a Group 2 activity for 1 CPD credit suitable for inclusion in an individual pharmacist's CPD plan.
Accreditation number: A1210AP1.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

Suicide in Australia – an overview :: Professor Nerida Smith : 27/9/2012 : This AusPharm CE topic, 'Suicide in Australia – an overview', has been put together for us by Professor Nerida Smith.

More than 2,500 Australians die from suicide annually, with many of the several hundred people attempting suicide daily being hospitalised.

On completing this activity you should be able to describe the:

characteristics of suicide in Australia
risk factors, triggers, warming signs and signs of imminent risk in relation to suicide
strategies used to prevent suicide
examples of suicide prevention training
examples of sources of crisis help and suicide prevention information in Australia.

The Competency Standards addressed by this activity include (but may not be limited to): 1.1, 1.2, 1.3, 1.5, 4.2, 4.3, 6.1, 6.2, 6.3, 7.1 7.2, 7.3, 8.1, 8.3.

This activity has been accredited by the Australian College of Pharmacy as a Group 2 activity for 2 CPD credits suitable for inclusion in an individual pharmacist's CPD plan.
Accreditation number: A1210AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 51 :: Chris Alderman : 13/9/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 51.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 47-2 → 47-5 ⇔ July/August 2012).

You can access these E-Bulletins individually here or as a group here (the Digest pdf includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Discuss the clinical pharmacology of vemurafenib
Discuss principle of dose adjustment of antibiotics in renal impairment
Describe therapeutic drug monitoring approaches used during antibiotic treatment in renally impaired people
Outline clinical issues relating to the use of low molecular weight heparin products in people with liver disease.

This activity has been accredited by the Australian College of Pharmacy as a Group 2 activity for 1 CPD credit suitable for inclusion in an individual pharmacist's CPD plan.
Accreditation number: A1209AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 50 :: Chris Alderman : 30/8/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 50.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 46-10 → 47-1 ⇔ June/July 2012).

You can access these E-Bulletins individually here or as a group here (the Digest pdf includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Discuss the clinical pharmacology of riluzole
Describe the characteristics of a COPD action plan
Understand clinical issues relating to the use of lactose containing medication products for those with lactose intolerance
Discuss the management of calciphylaxis.

This activity has been accredited by the Australian College of Pharmacy as a Group 2 activity for 1 CPD credit suitable for inclusion in an individual pharmacist's CPD plan.
Accreditation number: A1208AP1.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

The Management of Neuropathic Pain :: Angus Thompson : 16/8/2012 : This AusPharm CE topic is The Management of Neuropathic Pain - it's been put together for us by Angus Thompson.

"Optimising management of pain has become an increasing priority for many health professionals and health systems around the world."

The Learning Objectives for this activity are:

Describe the typical presenting features of neuropathic pain
Outline the advantages and disadvantages of key therapy options for neuropathic pain
Identify opportunities to optimise the management of neuropathic pain.

The Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 7.1.2, 7.1.3, 7.2.2, 7.2.3.

This activity has been accredited by the Australian College of Pharmacy as a Group 2 activity for 1 CPD credit suitable for inclusion in an individual pharmacist's CPD plan.
Accreditation number: A1208AP0.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 49 :: Chris Alderman : 2/8/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 49.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 46-6 → 46-9 ⇔ May/June 2012).

You can access these E-Bulletins individually here or as a group here (this Digest pdf includes the bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Discuss the clinical pharmacology of apixaban
Describe current developments regarding dextropropoxyphene products in Australia
Understand principles relevant to the systemic absorption of drugs after ocular administration
Outline important clinical issues relating to antibiotic resistance.

This activity has been accredited by the Australian College of Pharmacy as a Group 2 activity for 1 CPD credit suitable for inclusion in an individual pharmacist's CPD plan.
Accreditation number: A1207AP1.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

Ten possible questions for the person with hypertension :: Jenny Gowan : 19/7/2012 : This AusPharm CE topic is Ten possible questions for the person with hypertension - it's been put together for us by Dr Jenny Gowan.

"Cardiovascular disease (CVD) is the term used for heart, stroke and blood vessel diseases. It is the leading cause of death in Australia, accounting for 33% of all deaths in Australia in 2009. Cardiovascular disease is one of Australia's largest health problems."

The Learning Objectives for this activity are:

To select relevant counselling points when talking to people about optimum blood pressure control
To list targets for optimum blood pressure levels
To assist in optimum choice of medications for hypertension
To identify and predict adverse effects from medications used to manage hypertension
To refer patients for appropriate assessment to optimise their risk management.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 1.3, 2.1, 4.2, 6.1, 5.2.6.3, 7.1, 7.2.

This activity has been accredited by the Australian College of Pharmacy as a Group 2 activity for 2 CPD credits suitable for inclusion in an individual pharmacist's CPD plan.
Accreditation number: A1207AP.

Under the auspices of the Australian Pharmacy Council, the Australian College of Pharmacy may accredit continuing professional development for pharmacists that is eligible to be used as supporting evidence of continuing competence.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 48 :: Chris Alderman : 5/7/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 48.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 46-2 → 46-5 ⇔ April/May 2012).

You can access these E-Bulletins individually here or as a group here (this pdf Digest includes the bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

Discuss the clinical pharmacology of fampridine and linagliptin
Describe the effects of renal impairment upon bleeding risk associated with dabigatran
Outline recent developments in the understanding of weight gain associated with antipsychotic drugs.

This activity has been accredited for 0.5 hours of Group 2 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022J.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

Discontinuation of medications - Deprescribing :: Debbie Rigby : 21/6/2012 : Learning objectives

After completing this activity, pharmacists should be able to:

Describe deprescribing principles
Prioritise and plan a deprescribing regimen
Identify the risks associated with deprescribing
Counsel patients on the management of rebound symptoms.

This activity has been accredited for 0.75 hours of Group 2 CPD (or 1.5 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022I.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.1, 4.2, 6.1, 6.2, 7.1, 7.2.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 47 :: Chris Alderman : 31/5/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 47.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 45-10 → 46-1 ⇔ April 2012).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

Discuss the clinical pharmacology of ticagrelor
Outline the characteristics and management of postural hypotension
Understand recent changes to labelling requirements for statins, in line with FDA requirements
Describe the theoretical and clinical basis for a possible interaction between triptans and SSRIs.

This activity has been accredited for 0.5 hours of Group 2 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022H.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

Issues around drug dosing in women who are pregnant :: Ella van Tienen : 17/5/2012 : The latest AusPharm CE topic is Issues around drug dosing in women who are pregnant - it’s been put together for us by Ella van Tienen.

Whether to use a medication during pregnancy can be a source of concern for both patients and healthcare providers. It is estimated that around 59% of women are prescribed a medication other than vitamins at some time during their pregnancy, and it is expected that an even greater proportion take over the counter preparations.

Learning Objectives: On completion of this module, pharmacists should be able to

Recognise factors impacting on safely selecting and using medications in pregnancy
Understand the physiological changes that occur during pregnancy
Discuss the role of preconception care.

This activity has been accredited for 0.625 hours of Group 2 CPD (or 1.25 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022G.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 46 :: Chris Alderman : 3/5/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 46.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 45-6 → 45-9 ⇔ March 2012).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

Understand potential associations between clostridium difficile infection and PPI use
Discuss the approach to pre-admission pharmact assessment for elective surgery patients
Outline the clinical features of Dopamine Dysregulation Syndrome (DDS)
Describe the clinical presentation and management of bullous pemphigoid.

This activity has been accredited for 0.375 hours of Group 2 CPD (or 0.75 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022F.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 45 :: Chris Alderman : 12/4/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 45.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 45-2 → 45-5 ⇔ Feb 2012).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

Outline the clinical pharmacology of indacaterol
Identify drugs that may cause diarrhoea
Discuss the use of bisphosphonates in the context of renal impairment
Describe treatments for age-related macular degeneration.

This activity has been accredited for 0.5 hours of Group 2 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022E.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

Issues around drug dosing in women who are breast feeding :: Ella van Tienen : 22/3/2012 : The latest AusPharm CE topic is Issues around drug dosing in women who are breast feeding - it's been put together for us by Ella van Tienen.

"Breastfeeding is the best method of feeding infants in terms of cost, convenience and health benefits for both the infant and mother. Current recommendations suggest that in the absence of contraindications, women should exclusively breastfeed their infants for the first six months of life, and continue to breastfeed with complementary foods for up to two years. Many mothers are likely to need to take some form of medication during this time."

The Learning Objectives for this activity are:

Recognise factors impacting on safely selecting and using medications in breastfeeding
Understand the issues surrounding contraception when breastfeeding
Discuss the role of galactogogues in promoting lactation.

Click here to do this Continuing Education activity. Or, if you prefer, you might like to take a look at our other CE activities here .

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 44 :: Chris Alderman : 1/3/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 44.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 44-8 → 44-10 ⇔ Nov-Dec 2011).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

Describe recent findings with respect to the effects of dietary sodium restriction
Outline potential adverse interactions between alcohol and a range of medicinal drugs
Understand the practical application of the recently promulgated updated “Beers” criteria
Discuss the relationship between citalopram treatment and QT prolongation.

This activity has been accredited for 0.5 hours of Group 2 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022C.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

Persistent pain management in older people :: Jenny Gowan : 16/2/2012 : This AusPharm CE topic is Persistent pain management in older people - it's been put together for us by Dr Jenny Gowan.

"Pain is not necessarily part of ageing but there is a higher prevalence of pain in older people, often under-reported, under-recognised, can be under-treated and older people are likely to experience more adverse treatment effects"

The Learning Objectives for this activity are:

To recognise the impact of persistent pain on quality of life in older people
To describe essential features of pain assessment
To assist in optimum choice of medications for pain management
To identify and predict adverse effects from medications used to manage pain
To refer patients for appropriate assessment to optimise their management of pain.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 1.3, 4.2, 7.1, 7.3.

This activity has been accredited for 1 hour of Group 2 CPD (or 2 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan.
Accreditation number: CX120022B.

PSA is authorised by the Australian Pharmacy Council to accredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

RGH Pharmacy E-Bulletin CPD Digest - Issue No 43 :: Chris Alderman : 2/2/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 43.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 44-4 → 44-7 ⇔ Oct-Nov 2011).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

Understand general principles relating to the safety of drug treatment during pregnancy
Described the clinical pharmacology of zonisamide
Discuss the use of parenteral iron preparations for the management of iron deficiency anaemia
List issues that might impact of the drug interactions between antibiotic treatment and warfarin.

This activity has been accredited for 0.5 hours of Group 2 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022A.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

Click here to do this Continuing Professional Development activity.

About this page

These activities will take approximately 30 minutes to complete and has been formally recognised by the Pharmaceutical Society of Australia (Recognition No: CR08-0012 : 1 CPD&PI point), The Australian Association of Consultant Pharmacy and The Australian College of Pharmacy Practice and Management. To add your PSA, AACP or ACPPM member number to our database (so you can receive credit for completing this activity) click here.